Skip to main content
Log in

Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The pharmacokinetics of a single i. v. dose of dlbisoprolol 0.16 mg·kg−1 ideal body weight has been studied in 8 obese women (mean weight 91 kg; 161% of ideal body weight) and 8 non-obese women (51 kg; 94% of ideal body weight).

Compared to the controls, the obese subjects showed an increase in the total apparent volume of distribution (Vz) (182 vs 135 1) and a decrease in Vz per kg body weight (2 vs 2.7 l·kg−1). There was a negative correlation between Vz l·kg−1 and the percentage of ideal body weight (r=−0.672). Total body clearance was increased, but t1/2 and renal clearance was unchanged.

It is concluded that tissue diffusion of bisoprolol in obese subjects is limited, despite its lipophilicity, possibly because of alteration in the blood flow to adipose tissue produced by bisoprolol.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Cheymol G (1988) Drug pharmacokinetics in the obese. Fundam Clin Pharmacol 2: 239–256

    Google Scholar 

  2. Abernethy DR, Greenblatt DJ (1986) Drug disposition in obese humans: an update. Clin Pharmacokinet 11: 199–213

    Google Scholar 

  3. Abernethy DR, Greenblatt DJ, Divoll M, Harmatz JS, Shader RI (1981) Alterations in drug disposition and clearance due to obesity. J Pharmacol Exp Ther 217: 681–685

    Google Scholar 

  4. Abernethy DR, Greenblatt DJ, Smith TB (1981) Digoxin disposition in obesity: clinical pharmacokinetic investigation. Am Heart J 102: 740–744

    Google Scholar 

  5. Bowman SL, Hudson SA, Simpson G, Munro JF, Clements JA (1986) A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. Br J Clin Pharmacol 21: 529–532

    Google Scholar 

  6. Cheymol G, Poirier JM, Barré J, Pradalier A, Dry J (1987) Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. J Clin Pharmacol 27: 874–879

    Google Scholar 

  7. Anonymous (1959) Weights of insured persons in the United States associated with lowest mortality. Stat Bull Metrop Insur Co 40 November–December

  8. Hinderliter AL, Fitzpatrick MA, Schork N, Julius S (1987) Research utility of non-invasive methods for measurement of cardiac output. Clin Pharmacol Ther 41: 419–425

    Google Scholar 

  9. Poirier JM, Perez M, Cheymol G, Jaillon P (1988) Rapid and sensitive high performance liquid chromatographic determination of bisoprolol in plasma and urine. J Chromatogr 426: 431–437

    Google Scholar 

  10. Gomeni R (1984) Pharm: an interactive graphic program for individual and population pharmacokinetic parameter estimation. Comput Biol Med 14: 25–34

    Google Scholar 

  11. Leopold G (1986) Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol 8 [Suppl 11]: S16-S20

    Google Scholar 

  12. Leopold G, Pabst J, Ungethum W, Burhing KU (1987) Basic pharmacokinetics of bisoprolol a new highly β1 selective adrenoreceptor antagonist, J Clin Pharmacol 26: 616–621

    Google Scholar 

  13. Womersley J, Durnin J, Body K, Mahaffly M (1976) Influence of muscular development, obesity and age on the fat free mass of adults. J Appl Physiol 41: 223–229

    Google Scholar 

  14. Woods PB, Robinson ML (1981) An investigation of the comparative liposolubilities of β-adrenoreceptor blocking agents. J Pharm Pharmacol 33: 172–173

    Google Scholar 

  15. Messerli FH, Sundgoard-Russe K, Reisin E, Dreslinski G, Dunn FG, Frohlich E (1983) Disparate cardiovascular effects of obesity and arterial hypertension. Am J Med 74: 808–812

    Google Scholar 

  16. Belfrage E (1978) Vasodilatation and modulation of vasoconstriction in canine subcutaneous adipose tissue caused by activation of βadrenoreceptors. Acta Physiol Scand 102: 459–468

    Google Scholar 

  17. Rosell S, Belfrage E (1979) Blood circulation in adipose tissue. Phys Res 59: 1078–1104

    Google Scholar 

  18. Krämer B, Balser J, Stubbig K, Krämer G, Kübler WY (1986) Comparison of bisoprolol with other β-adrenoceptor blocking drugs. J Cardiovasc Pharmacol 8 [Suppl 11]: S46-S57

    Google Scholar 

  19. Chang PC, Van Veen S, Vermeij P, Van Brummelen P (1986) Double-blind comparison of the β1-selectivity of single doses of bisoprolol and atenolol. J Cardiovasc Pharmacol 8 [Suppl 11]: S58-S60

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Le Jeunne, C., Poirier, J.M., Cheymol, G. et al. Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers. Eur J Clin Pharmacol 41, 171–174 (1991). https://doi.org/10.1007/BF00265912

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00265912

Key words

Navigation